Skip to main content
    T

    Tonix Pharmaceuticals Holding Corp (TNXP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.88
    -0.13 (-4.32%)

    Market Cap: $58.49M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tonix Pharmaceuticals Holding Corp (TNXP) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Tonix Pharmaceuticals Holding (TNXP) trades at 1.2x sales and 0.3x book value. Its P/B of 0.3x is below its 5-year median of 0.5x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales1.2x
    Price to book0.3x
    EV/FCF0.6x
    PEGN/A
    FCF yield-320.2%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/B0.3x0.5xN/A
    Medians of month-end values through Oct 2026: 49 months (5-year).

    Valuation History

    Over the 6 of the 10 year ends shown that have a P/B, its P/B ranged from 0.5x in 2024 to 45.3x in 2016.

    Year endPriceP/SP/B
    2025$15.629.3x0.5x
    2024$32.98N/A0.5x
    2023$1,291.67N/AN/A
    2022$7,808.49N/AN/A
    2021$229,662.33N/A0.7x
    2020$433,385.72N/A1.4x
    2019$751,201.92N/AN/A
    2018$14,125,164.37N/A5.1x
    2017$221,508,259.37N/AN/A
    2016$301,829,080.37N/A45.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TNXP

    Is TNXP stock overvalued?

    GNG's valuation label for TNXP is Overvalued.

    What is TNXP's price to sales ratio?

    Tonix Pharmaceuticals Holding has a price to sales ratio of 1.2x.